CR20210670A - Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer - Google Patents

Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer

Info

Publication number
CR20210670A
CR20210670A CR20210670A CR20210670A CR20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A
Authority
CR
Costa Rica
Prior art keywords
mat2a
methods
treating cancer
inhibitors
compounds
Prior art date
Application number
CR20210670A
Other languages
English (en)
Inventor
Mingzong Li
Zhihua Sui
Zenon D Konteatis
Jeremy M Travins
Samuel K Reznik
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20210670A publication Critical patent/CR20210670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona compuestos de acuerdo con la Fórmula I, Fórmula II, y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la metionina adenosiltransferasa isoforma 2A (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para el tratamiento del cáncer, incluidos algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
CR20210670A 2019-05-31 2020-05-29 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer CR20210670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855395P 2019-05-31 2019-05-31
PCT/US2020/035036 WO2020243376A1 (en) 2019-05-31 2020-05-29 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
CR20210670A true CR20210670A (es) 2022-02-11

Family

ID=72179154

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210670A CR20210670A (es) 2019-05-31 2020-05-29 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer

Country Status (16)

Country Link
US (1) US20220251081A1 (es)
EP (1) EP3976611A1 (es)
JP (1) JP2022534989A (es)
AR (1) AR119046A1 (es)
AU (1) AU2020284018A1 (es)
BR (1) BR112021023825A2 (es)
CA (1) CA3142340A1 (es)
CO (1) CO2021017981A2 (es)
CR (1) CR20210670A (es)
IL (1) IL288395A (es)
JO (1) JOP20210317A1 (es)
MA (1) MA56050A (es)
PE (1) PE20220387A1 (es)
SG (1) SG11202112952SA (es)
TW (1) TW202110841A (es)
WO (1) WO2020243376A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117544A1 (es) * 2018-12-27 2021-08-11 Agios Pharmaceuticals Inc Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
CN115960098A (zh) * 2020-09-11 2023-04-14 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
JP2024502097A (ja) * 2020-12-31 2024-01-17 南京再明医薬有限公司 三環式化合物とその用途
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022228515A1 (zh) * 2021-04-30 2022-11-03 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
EP4434989A1 (en) * 2021-12-21 2024-09-25 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Methionine adenosyltransferase 2a heterocyclic inhibitor
WO2023143356A1 (zh) * 2022-01-26 2023-08-03 勤浩医药（苏州）有限公司 用于治疗mtap缺失型癌症的甲硫氨酸腺苷转移酶2a抑制剂
CN118742550A (zh) * 2022-03-11 2024-10-01 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
TW202415370A (zh) * 2022-10-13 2024-04-16 南韓商韓美藥品股份有限公司 新穎三環衍生物化合物以及其應用
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN116239541B (zh) * 2023-05-11 2023-07-21 英矽智能科技(上海)有限公司 N-苯基-2-氧代喹唑啉类化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
CN1275964C (zh) * 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
WO2008156726A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
AU2019243289B2 (en) * 2018-03-30 2023-01-12 Les Laboratoires Servier Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer

Also Published As

Publication number Publication date
AR119046A1 (es) 2021-11-17
PE20220387A1 (es) 2022-03-18
EP3976611A1 (en) 2022-04-06
MA56050A (fr) 2022-04-06
JOP20210317A1 (ar) 2023-01-30
SG11202112952SA (en) 2021-12-30
BR112021023825A2 (pt) 2022-02-08
US20220251081A1 (en) 2022-08-11
TW202110841A (zh) 2021-03-16
CO2021017981A2 (es) 2022-04-19
JP2022534989A (ja) 2022-08-04
WO2020243376A1 (en) 2020-12-03
IL288395A (en) 2022-01-01
AU2020284018A1 (en) 2022-01-27
CA3142340A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
CR20210670A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
SA521422405B1 (ar) Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
NZ777925A (en) Deoxy- cytidine or uridine derivatives for use in cancer therapies
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2024004874A (es) Compuestos heterociclicos para uso en el tratamiento de cancer.